ODTX — Odyssey Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $836.87m
- $705.50m
- $2.98m
Annual cashflow statement for Odyssey Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -0.125 | -0.126 | -129 | -149 |
| Depreciation | ||||
| Non-Cash Items | 0.02 | 0.007 | 9.96 | 19 |
| Unusual Items | ||||
| Purchased R&D | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | 0.002 | 0.001 | -3.31 | -4.73 |
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Change in Other Liabilities | ||||
| Cash from Operating Activities | -0.1 | -0.113 | -117 | -129 |
| Capital Expenditures | -0.013 | -0.005 | -0.764 | -1.23 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | 0 | -0.16 | 97.5 | -103 |
| Sale of Fixed Assets | ||||
| Sale/Maturity of Investment | ||||
| Purchase of Investments | ||||
| Cash from Investing Activities | -0.013 | -0.165 | 96.8 | -104 |
| Financing Cash Flow Items | — | — | -1.01 | 0 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 0.183 | 0.092 | 27 | 216 |
| Foreign Exchange Effects | ||||
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 0.07 | -0.186 | 6.34 | -17.4 |